
Outlook Therapeutics Reports $20.3M Q3 Loss, FDA Approval
• Outlook Therapeutics reported a $20.3 million loss for the third quarter, coinciding with the FDA approval of its intravitreal treatment, LYTENAVA. • Management projects that LYTENAVA could generate over $500 million in annual U.S. sales by 2030 due to its direct-to-retina delivery method. • The company plans to apply for a permanent reimbursement code by October 1, a critical step for ensuring market access and revenue predictability.
Read story





